Patent classifications
C07C63/331
NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME
The present invention relates to a novel compound, which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300, through structure analysis of HAT p300. The novel compound of the present invention has a remarkably excellent effect of inhibiting HAT p300 activity and thus can be very effectively used in the prevention, alleviation, or treatment of fibrosis, which is a disease associated with activation of HAT p300.
NOVEL COMPOUND FOR INHIBITING HISTONE ACETYLTRANSFERASE P300 AND ANTI-FIBROSIS COMPOSITION COMPRISING SAME
The present invention relates to a novel compound, which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300, through structure analysis of HAT p300. The novel compound of the present invention has a remarkably excellent effect of inhibiting HAT p300 activity and thus can be very effectively used in the prevention, alleviation, or treatment of fibrosis, which is a disease associated with activation of HAT p300.
Chromium-based metal-organic frameworks for water adsorption-related applications and gas storage
Embodiments of the present disclosure describe a metal-organic framework (MOF) composition comprising a plurality of metal clusters, wherein the metal is chromium; and one or more tetratopic ligands; wherein the metal clusters and ligands associate to form a MOF with soc topology. A method of making a MOF comprising contacting a template MOF of formula Fe-soc-MOF and a reactant including chromium in a presence of dimethylformamide sufficient to replace Fe with Cr and form an exchanged MOF of formula Cr-soc-MOF. A method of sorbing water vapor comprising exposing a Cr-soc-MOF to an environment; and sorbing water vapor using the Cr-soc-MOF.
Chromium-based metal-organic frameworks for water adsorption-related applications and gas storage
Embodiments of the present disclosure describe a metal-organic framework (MOF) composition comprising a plurality of metal clusters, wherein the metal is chromium; and one or more tetratopic ligands; wherein the metal clusters and ligands associate to form a MOF with soc topology. A method of making a MOF comprising contacting a template MOF of formula Fe-soc-MOF and a reactant including chromium in a presence of dimethylformamide sufficient to replace Fe with Cr and form an exchanged MOF of formula Cr-soc-MOF. A method of sorbing water vapor comprising exposing a Cr-soc-MOF to an environment; and sorbing water vapor using the Cr-soc-MOF.
Nanohoop compounds for use in biotechnology and methods of making and using the same
Disclosed herein are embodiments of nanohoop compounds and conjugates thereof that can be used myriad biological applications. The nanohoop compounds described herein can exhibit beneficial properties that are useful in biotechnology, such as a fluorescent tag, probe, or label.
Nanohoop compounds for use in biotechnology and methods of making and using the same
Disclosed herein are embodiments of nanohoop compounds and conjugates thereof that can be used myriad biological applications. The nanohoop compounds described herein can exhibit beneficial properties that are useful in biotechnology, such as a fluorescent tag, probe, or label.
SUBSTRATE PROCESSING APPARATUS, RAW MATERIAL CARTRIDGE, SUBSTRATE PROCESSING METHOD, AND RAW MATERIAL CARTRIDGE MANUFACTURING METHOD
A substrate processing apparatus includes: a chamber; and a processing gas supply unit connected to the chamber via a processing gas supply flow path and configured to supply a processing gas. The processing gas supply unit includes a raw material cartridge that includes a raw material tank that accommodates a porous member containing a metal-organic framework adsorbed with gas molecules of a raw material of the processing gas; a main body configured to communicate the raw material tank and the processing gas supply flow path with each other when the raw material cartridge is attached; and a desorption mechanism configured to desorb the gas molecules of the raw material of the processing gas and allow the gas molecules to flow out as the processing gas to the processing gas supply flow path while the raw material cartridge is attached to the main body.
METAL-ORGANIC FRAMEWORK HAVING TEREPHTHALIC ACID BASED LIGAND
Despite the fact that the amount and type of gas to be stored may vary in accordance with the type of substituent, metal-organic frameworks only using a terephthalic acid having substituents within the limited range have been produced conventionally. An object of the present invention is to provide a novel metal-organic framework using a 2,5-disubstituted terephthalic acid. A metal-organic framework comprising a carboxylate ion of formula (I) and a multivalent metal ion bound to each other is a novel metal-organic framework, enabling a gas such as hydrogen and nitrogen to be store efficiently. (wherein in formula (I), X is an unsubstituted or substituted cycloalkyl group, an unsubstituted or substituted aryl group, an unsubstituted or substituted heterocyclyl group or —Si(R.sup.1) (R.sup.2) (R.sup.3) ; and Y is a single bond, an alkylene group, —O—, —S—, —S(O)—, —SO.sub.2—, —N(R.sup.4)— or a group formed by a combination thereof; provided that X—Y— is a phenyl group, a benzyloxy group, a pyrazol-1-yl group or a group of formula (II) except for a case where m is 3, 6, 8, 9, 10, 11 and 12).
##STR00001##
INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.
INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.